ArticleJournal of separation science2026
Losartan API and Nitrosamines Impurities-Stability Profile Investigation Using HPLC, LC-MS, and In Silico Assessment.
Article in Journal of separation science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From "Undetectable" to "Sensitive Detection": Advances in Derivatization Techniques for LC-MS Analysis of Genotoxic Impurities.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nitrosamines are potent genotoxic impurities with well reported mutagenic and carcinogenic effects. Their presence has been detected in several pharmaceutical products among them losartan, an angiotensin II receptor blocker. Considering the risks already reported for these impurities, the present study aimed to investigate the influence of four common nitrosamines-N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), N-nitrosodiisopropylamine (NDIPA), and N-nitrosodibutylamine (NDBA)-in the stability profile of losartan API. Quantitative assay was conducted through HPLC and LC-MS, with focus on monitoring degradation rate and degradation products under influence of nitrosamines. Predictive data by in silico investigation employing Zeneth Nexus and Spartan were simultaneously studied, considering degradation products, fragmentation pathway and nitrosamines reactivity. The drug residual content showed variability depending on the nitrosamine evaluated and the stressing condition applied. From photolysis, for example the residual content ranged 80%-90%, with a greater decomposition in samples containing nitrosamines. A greater decomposition was also observed in oxidative degradation, with exception for samples containing NDMA. Acid and basic media caused a significant decomposition, with the residual losartan content in a range of 41%-52% and 28%-51%, respectively. From LC-MS analyzes, these impurities were mostly not detected in the degraded samples, suggesting their consumption during the reaction due to their reactivity. A protective effect from nitrosamines can be also reported possibly due to their reactivity against the stressing factor. Seven degradation products were structurally proposed by LC-MS at m/z 449, m/z 447, m/z 366, m/z 338, m/z 274, m/z 391, and m/z 341, some of them predicted computationally by Zeneth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.